TABLE 1
Selective recommendations of key guidelines
related to chemotherapy
MASCC/ESMO
HEC - including AC –
(and carboplatin with AUC
≥4mg/ml/min; NCCN only)
Acute phase
5-HT 3 RA + NK 1 RA + Dex +/-
olanzapine
MASCC/ESMO: Palonosetron is the
preferred 5-HT 3 RA when NK 1 RA
is not available
NCCN: Netupitant and rolapitant
are effective in the prevention of
delayed nausea
Delayed phase (non-AC HEC):
Dex or (if APR used in day 1, Dex +
MCP or APR + Dex) +/- olanzapine
Delayed phase (AC regimes):
None or (if APR used in day 1, Dex or
APR) +/-Olanzapine
MEC
NCCN: Palonosetron- and
granisetron extended-release
injections are the preferred 5-HT 3
RAs for delayed nausea
Acute phase:
5-HT 3 RA + Dex
Carboplatin-treated patients:
5-HT 3 RA + NK 1 RA + Dex
Delayed phase:
Carboplatin-treated patients: None
or (if APR used in day 1, APR)
Oxaliplatin-, anthracycline-,
cyclophosphamide-treated patients:
DEX can be considered
20 | 2019 | hospitalpharmacyeurope.com